By Editor Panel, Lifescience Outlook, Editor
The healthcare solutions company is combining artificial intelligence, data analytics, and smarter pharmaceutical logistics to help medicines reach patients faster while improving supply chain efficie...
By Editor Panel, Lifescience Outlook, Editor
The pharmaceutical companies are combining HDAC expertise and mechanistic AI to explore potential treatments for neuromuscular, fibrotic, and rare diseasesSan Francisco and Milan, 6 October 2026 – Dru...
By Editor Panel, Lifescience Outlook, Editor
The acquisition brings together reusable shipping systems and validated packaging for pharmaceutical deliveries from pallets to patientsMannheim, Germany, 29 September 2026 – The pharmaceutical indust...
By Editor Panel, Lifescience Outlook, Editor
New EHR tools and a health information network aim to simplify clinical workflows, connect patient data, and support smarter healthcare decisionsOrlando, 24 September 2026 – Healthcare organizations m...
By Editor Panel, Lifescience Outlook, Editor
Smarter data analysis, faster research, and growing investment are giving artificial intelligence a bigger role in the search for new medicinesBoston, Massachusetts, 15 September 2026 – Artificial int...
By Editor Panel, Editor, Lifescience Outlook
By Editor Panel, Editor, Lifescience Outlook
By Editor Panel, Editor, Lifescience Outlook
By Editor Panel, Editor, Lifescience Outlook
By Julia Amann, Project Manager Strategy, Careum Foundation
Challenging AIIn drug discovery, an AI-generated target ranking can influence experiments, portfolio choices and capital allocation long before a candidate enters clinical development. The question is...
By Neil Kubica, Therapeutics Division Lead, General Inception
Artificial intelligence is rapidly lowering the cost of generating plausible hypotheses in drug discovery. Models can nominate targets, integrate biological and chemical data, design molecules, and su...
By Neil A. Bhowmick, Chief Scientific Officer, Kairos Pharma Ltd.
RNA-based medicines have developed into a broad therapeutic platform. Clinically established modalities include antisense oligonucleotides, small interfering RNAs, messenger RNAs that direct transient...
By Polly Astill, Marketing Campaign Manager, Sygnature Discovery
Biomarker discovery lies at the heart of the translational gap in drug development. Too often, programs stall, and compounds fail in late-stage trials. Retrospective analyses repeatedly point to the s...
By Daniel-Paul Bednarík, PhD, Chief Technology Officer, Black Canyon Bio, Inc.
Developing a new medicine is difficult. Scientists must understand a disease, identify a biological target, find a compound or biologic that modulates it, and show that it is safe and effective. Most...
